Corporate Information – Page 14 – Alligator Bioscience

2021-11-29

Regulatory

Alligator announces preliminary outcome of rights issue

rights issue of shares (the “Rights Issue”) ended on 26 November 2021. The preliminary outcome shows that the Rights Issue has been oversubs ...

2021-11-12

Poster presentation to highlight the ability of ATOR-1017 to activate and rescue tumor infiltrating exhausted T cells in synergy with PD-1 L ...

2021-11-12

Poster Presentation to highlight our Neo-X-Prime™ platform that aims to enable antigen presenting cells to efficiently enhance priming of tu ...

2021-11-12

Poster presentation to highlight the design of Optimize-1, evaluating mitazalimab in combination with chemotherapy in patients with metastat ...

2021-11-12

Data support Advancement into the Clinic Lund, Sweden, and Seattle Washington, November 12, 2021 – Alligator Bioscience AB (“Alligator”) and ...

2021-11-12

Today is the first day of the subscription period in Alligator Bioscience AB (publ)'s ("Alligator" or the "Company") rig ...

2021-11-10

Lund, Sweden, November 10, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Offi ...

2021-11-08

First Patient Dosed in Study Evaluating Mitazalimab in Combination with Cancer Vaccine for Patients with Pancreatic Cancer Lund, Sweden, N ...

2021-11-08

Today, on 8 November 2021, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...